BioMarin: Pooled Data Offer Optimism For Drisapersen Approval Despite Phase III Failure
Executive Summary
During its R&D presentation Dec. 10, BioMarin explained the rationale behind its buyout offer for Prosensa and its Phase III candidate for Duchenne muscular dystrophy. Despite a Phase III failure, company thinks pooled data analysis shows sizeable benefit in younger patients and even long-term treatment effect in more advanced patients.